ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

VXRT Vaxart Inc

0,8069
-0,0211 (-2,55%)
Zuletzt aktualisiert: 18:50:58
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Vaxart Inc VXRT NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,0211 -2,55% 0,8069 18:50:58
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,821 0,802 0,838 0,828
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
23.5.202422:01GLOBEVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing..
13.5.202422:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.5.202422:03EDGAR2Form 8-K - Current report
13.5.202422:01GLOBEVaxart Provides Business Update and Reports First Quarter..
13.5.202413:10IHMARKETNEWSU.S. Futures Climb Amid High Expectations for Inflation..
07.5.202414:00GLOBEVaxart to Host First Quarter 2024 Business Update and..
30.4.202414:00GLOBEVaxart Announces Positive Results for Its Bivalent Norovirus..
27.3.202413:00GLOBEVaxart to Present at World Vaccine Congress Washington 2024..
20.3.202413:00GLOBEVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing..
14.3.202421:01GLOBEVaxart Provides Business Update and Reports Full Year 2023..
14.3.202412:41IHMARKETNEWSU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil..
07.3.202414:00GLOBEVaxart to Host Full Year 2023 Business Update and Financial..
06.3.202415:23EDGAR2Form 8-K - Current report
06.3.202414:00GLOBEVaxart, Inc. Appoints Steven Lo as President, Chief..
29.2.202422:30EDGAR2Form 8-K - Current report
15.2.202422:10EDGAR2Form 8-K - Current report
13.2.202423:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05.2.202414:00GLOBEVaxart Announces Publication in Vaccines of Non-Human..
02.2.202422:49EDGAR2Form 8-K/A - Current report: [Amend]
19.1.202423:14EDGAR2Form 8-K - Current report
19.1.202422:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
19.1.202414:30GLOBEVaxart Receives $9.27 Million BARDA Project NextGen Award to..
16.1.202423:18EDGAR2Form 8-K - Current report
16.1.202415:25GLOBEVaxart Announces $10.0 Million Registered Direct Offering..
16.1.202415:22GLOBEVaxart, Inc. Announces Management Change
16.1.202415:19EDGAR2Form 8-K - Current report
21.12.202314:00GLOBEVaxart Announces Last Subject Dosed in Phase 1 Trial of Its..
02.11.202321:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02.11.202321:11EDGAR2Form 8-K - Current report
02.11.202321:01GLOBEVaxart Provides Business Update and Reports Third Quarter..
02.11.202313:00GLOBEVaxart Doses First Subject in Phase 1 Trial of Its Norovirus..
26.10.202314:00GLOBEVaxart to Host Third Quarter 2023 Business Update and..
23.10.202323:09EDGAR2Form 8-K/A - Current report: [Amend]
23.10.202323:01EDGAR2Form 8-K - Current report
11.10.202314:00GLOBEVaxart to Present at World Vaccine Congress Europe 2023 on..
21.9.202314:00GLOBEVaxart to Participate in Fireside Chat at 2023 Cantor Global..
06.9.202322:43EDGAR2Form 8-K - Current report
06.9.202322:05GLOBEVaxart Announces Topline Data from the Phase 2 Challenge..
03.8.202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03.8.202322:20EDGAR2Form 8-K - Current report
03.8.202322:01GLOBEVaxart Provides Business Update and Reports Second Quarter..
02.8.202303:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.8.202303:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.8.202303:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.8.202303:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.8.202302:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.7.202314:00GLOBEVaxart to Host Second Quarter 2023 Business Update and..
26.7.202322:20EDGAR2Form 8-K - Current report
10.7.202322:12EDGAR2Form 8-K - Current report
06.7.202314:00GLOBEVaxart Announces Positive Preliminary Topline Data from..

Kürzlich von Ihnen besucht